A Multiple-Dose Study of LY3493269 in Healthy Participants

Phase 1 Terminated 42 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to conduct blood tests to measure how much LY3493269 is in the bloodstream and how the body handles and eliminates LY3493269 when administered orally as test compared to reference formulations in healthy participants in fed and/or fasted states. The study will also evaluate the safety and tolerability of LY3493269 in these participants. The study will last up to 43 days excluding the screening period.

Timeline

Start: 2023-03-23
Primary completion: 2023-06-20
Completion: 2023-06-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3493269	Unknown	4 mg	Oral
Background	Salcaprozate Sodium	Unknown	300 mg	Oral
Background	Sodium Caprate	Unknown	280 mg	Oral

Indications

No indication recorded.